Skip to main content
. 2019 Jun 18;10:2040620719854171. doi: 10.1177/2040620719854171

Figure 3.

Figure 3.

Therapeutic options for targeting myeloma epitopes, in this case, BCMA; CAR T-cells, bispecific T-cell engagers, bispecific antibodies and antibody–drug conjugates.

BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor- T cells; BiTES, Bispecific T-cell engagers.